UFP Technologies (UFPT) 2026年第三季度业绩电话会：内生增长11.1%及利润率扩张

核心要点

• 2026年第三季度销售额同比增长11.6%至1.724亿美元，其中包括11.1%的内生性增长。
• 毛利率从27.7%提升至29.4%，调整后营业利润增长14.5%，调整后营业利润率达到17.5%。
• 调整后摊薄每股收益为2.88美元。经营活动产生的现金流总计约3850万美元，季末杠杆率远低于1倍。
• 受病床及患者转运、心血管、感染控制和骨科应用领域双位数增长的提振，本季度医疗技术业务销售额增长12.5%。
• 管理层依然对包含收购在内的长期增长框架保持信心，即内生性增长6%–9%、总增长12%–18%。同时预计第四季度受季节性影响表现仍将偏弱。
• UFP Technologies 正在对 DAS Medical 的产能、塑料制造能力以及收购业务进行投资；与此同时，AJR 客户认证的延迟继续延缓向多米尼加共和国的产品转移进度。

关键财务数据

业务与运营表现

第三季度医疗技术销售额增长12.5%，各项产品组合需求普遍强劲。年初至今医疗技术业务增速达11.7%，与 UFP Technologies 前五大医疗技术客户的整体增速相当。

公司在病床及患者转运、心血管、感染控制和骨科应用领域均实现双位数增长。手术机器人业务表现符合管理层此前预期，即2026年整体持平至小幅下滑。

UFP Technologies 继续在多米尼加共和国推进新项目规模化，并改善原有传统业务的利润率。AJR 在美国和多米尼加共和国均取得显著的同比进展，但由于客户认证流程要求，劳动密集型产品的转移进度仍落后于计划。

在 DAS Medical 方面，公司在预期的双位数增长到来之前提前扩充产能和人员配置。管理层指出，一项长期客户协议、2026年启动项目的全年业绩贡献，以及新兴手术机器人平台，将成为2027年及以后的潜在增长引擎。

UFP Technologies 于8月收购了 CI Medical。该业务主要在注塑成型和挤出塑料组件上进行精密印刷，有效补充了公司不断扩张的塑料业务。结合2025年对 TPI 的投资，此次收购拓宽了 UFP Technologies 在注塑成型和医疗器械印刷领域的综合能力。

管理层展望

管理层重申其长期增长框架，即内生性增长6%–9%、含收购的总增长12%–18%。公司不提供季度或年度财务指引。

管理层预计第四季度受季节性影响表现仍将偏弱，部分原因在于多米尼加共和国业务规模扩大使其更容易受到节假日停工的影响。

在毛利率方面，管理层对28%–31%的目标区间依然保持信心，并表示该业务目前正趋稳在29%左右。根据客户优先级和认证时间安排，预计2027年将开展更多的 AJR 转移活动。

随着公司逐步消化近期的各项投资，SG&A 费用的增长预计将趋于平缓。一次性重叠的 CEO 过渡成本将逐步消除，但较高的网络安全支出仍将持续。第三季度 SG&A 费用包含约190万美元的额外工资与福利，以及约80万美元的非现金股权激励支出。

公司还在推进扩大信贷额度，以支持更大规模的收购。管理层表示，目前的信贷安排允许借款最高达 EBITDA 的3.25倍，并打算在更大规模上继续坚持现有的审慎收购策略。

风险与关注事项

• AJR 向多米尼加共和国转移产品的进度落后于计划，且仍取决于客户认证进展。
• 第四季度历来表现偏弱，多米尼加共和国假期的停工进一步加剧了季节性压力。
• 尽管管理层对较新平台抱有长期乐观态度，但预计2026年全年手术机器人业务将持平至下滑。
• 由于劳动密集型生产仍留在成本较高的地区，AJR 持续对利润率构成不利影响。
• 近期在管理层、网络安全、产能和核心能力方面的投资，导致 SG&A 费用在预期增长兑现前先行增加。

分析师问答要点

管理层将毛利率的改善归因于业务量的增长以及整个产品组合层面的成本削减，尽管尚未完全释放 AJR 产能转移的全部效益。

在资本配置方面，公司的轻资产模式使其在为内生性增长提供资金后，能够优先考虑收购。管理层表示收购储备项目十分活跃，UFP Technologies 现已能够寻求范围更广、规模更大的收购标的。

与薄膜、发泡材料和织物相比，UFP Technologies 在塑料、挤出和粘合剂领域的业务规模依然较小。管理层正评估通过内生性投资和并购两种方式来拓展这些能力，特别是在注塑成型领域。

管理层表示，客户在产品研发、新产品推出或订购模式方面的行为未发生重大变化。公司将继续集中资源，服务于那些致力于改善患者治疗效果并降低成本的客户需求。

财报电话会议完整实录

完整财报电话会议逐字稿

管理层陈述

Operator

Good day, and welcome to UFP Technologies' Third Quarter 2026 Earnings Conference Call. [Operator Instructions] Please note that this event is being recorded. I would now like to turn the conference over to Ron Lataille, Senior Vice President, Treasurer and Chief Financial Officer. Please go ahead.

Ronald Lataille

Thank you, operator. Good morning, and thank you for joining us on our 2026 third quarter earnings conference call. With me on today's call is our CEO, Mitch Rock. Today, we will make some forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, the accuracy of which is subject to risks and uncertainties.

Wherever possible, we will try to identify those forward-looking statements by using words such as believe, expect, anticipate, pursue, forecast and similar expressions. Our forward-looking statements are based on our estimates and assumptions as of today and should not be relied upon as representing our estimates or views on any subsequent date. Please refer to the cautionary statement regarding forward-looking information and the risk factors in our most recent 10-K and 10-Qs, including disclosure of the factors that could cause results to differ materially from those expressed or implied.

During this call, we will discuss non-GAAP financial measures, which include organic sales growth, adjusted gross margin, adjusted operating income, adjusted SG&A, adjusted EPS and EBITDA and adjusted EBITDA. A reconciliation of GAAP to non-GAAP measures discussed in this call is contained in the associated press release and is available in the Investor Relations section of our website. I'll now turn the call over to Mitch.

Mitchell Rock

Thank you, Ron. Good morning, everyone, and thank you for joining us. Our third quarter reflects solid execution across UFP and steady progress on our long-term growth strategy. Third quarter sales were $172.4 million, up 11.6%. Organic growth was 11.1%. Gross margin increased to 29.4%, adjusted operating income grew 14.5%, and adjusted earnings per share increased to $2.88. Year-to-date, sales are up 10.3%, to $500.6 million. MedTech grew 11.7%, and our top 5 MedTech customers collectively also grew 11.7%. What stands out to me is how broad the growth is. MedTech sales were up 12.5%, in the quarter with demand across the portfolio. One of the real strengths of UFP is that our growth does not depend on any single customer, program or end market. We were proud to be recognized by one of our top 5 customers with a supplier award for creating value through innovation and cost savings.

That's exactly what we're aiming for, line up with where our customers are going long term and help them scale while taking costs out. On operations, we are continuing to make progress. We are scaling new programs in the Dominican Republic. Margins are improving in our legacy UFP operations. And at AJR, we have made significant year-over-year progress, both in the U.S. and in the Dominican Republic. That said, we're behind schedule moving AJR activity to the Dominican Republic. We remain committed to finishing those transfers, scaling up operations and delivering the savings we anticipate. At the same time, we're investing ahead of growth in other parts of the business.

At DAS Medical, we are adding capacity ahead of anticipated double-digit growth, along with the people and capabilities to support it. And we are broadening what we can do. In August, we acquired CI Medical, a niche medical device printing business that prints on injection molded and extruded plastic components. CI Medical serves device development and low-volume, high-mix applications. It's a strong fit with our growing plastics business. We also see an opportunity to expand medical injection molding. Our 2025 investment in TPI gave us a strong initial position in this large and established market.

And CI Medical adds the printing capability that goes along with injection molded and extruded components. Together, they expand what we can offer our customers and add value across the UFP platform. Beyond these investments, acquisitions have always been a key part of our growth strategy, and we're positioning UFP to do more. We are making progress on several opportunities. And as UFP has grown, so has the size and range of the businesses we can take on. We remain disciplined on strategic fit and valuation. In parallel, we're working to expand our credit facility, which gives us room to invest in high-quality businesses that meet our criteria.

Between a strong, conservative balance sheet, a bigger team and our decentralized operating model, we believe we can bring on larger businesses and keep investing in organic growth. As we look to 2027, I'm optimistic. We have strong customer relationships, expanding capabilities, new capacity coming online, meaningful organic growth opportunities and an active acquisition pipeline. We also have areas where execution needs to improve, and we remain focused on those.

Our strategy remains consistent: grow with our customers, invest in our people and capabilities, improve our operations, make disciplined acquisitions and create long-term value for our shareholders. None of this happens without our thousands of team members around the world. I want to thank them for their commitment to our customers, to each other and to getting better every day. Thank you. And with that, I'll turn it over to Ron.

Ronald Lataille

Thank you, Mitch. With regard to operating results, as Mitch mentioned, overall sales were up 11.6%, fueled by strength in the patient beds and handling, cardiovascular, infection control and orthopedic submarkets. Organic sales growth for the quarter was strong at 11.1% as our launch programs accelerate, and we continue to improve efficiencies at AJR. Gross profit as a percentage of sales or gross margin increased to 29.4%, from 27.7% last year.

This improvement was despite continued margin headwind at AJR as high labor products scheduled to be transferred to the Dominican Republic continues to be contingent on customer qualification. SG&A expenses for our third quarter of 2026 increased by $4.1 million to $23.2 million. This is largely due to approximately $1.9 million in wages and benefits for back-office investments, increased members of our senior management team designed to accelerate growth and variable compensation as well as approximately $800,000 in noncash equity compensation caused partially by duplicate CEO equity costs.

On a sequential basis, SG&A remained relatively similar. Adjusted operating margin for the third quarter was 17.5% and adjusted earnings per diluted share outstanding was $2.88, up significantly from last year. We generated approximately $38.5 million in cash from operations during our third quarter. Capital expenditures were $3.9 million during our third quarter, and we ended with a leverage ratio of well under 1x. With that, I now turn it back to the operator for questions.

Operator

[Operator Instructions]

Our first question comes from the line of Justin Ages with CJS Securities.

Justin, will you please proceed with your question?

分析师问答

Justin Ages

Yes.

So you mentioned strength in patient beds and a couple of areas. Can you give us a sense on where robotic surgery growth was?

Mitchell Rock

Yes. So as Ron mentioned, we had broad growth in those 4 subsegments, actually double-digit growth. And as we have indicated throughout the year that 2026 is a flat to down year in robotic surgery. So the results were consistent with that.

Justin Ages

That's helpful. And then really strong free cash flow generation. And I know you talked about an active M&A pipeline. Can you kind of let us know about capital allocation priorities where you're looking at acquisitions or maybe instituting buybacks or anything like that?

Ronald Lataille

I would say broadly, we're focused on allocating capital to support organic growth. And as you know, we have a capital-light model. So that pivots our focus to acquisitions. We've been clear that we have an active pipeline, and we're positioning the business to do more.

Operator

Next question comes from the line of Brett Fishbin with KeyBanc.

Brett Fishbin

I wanted to just ask on AJR. I know you guys are progressing in moving some of the product lines offshore, not quite done. So I was just curious if you can give any updates on how it went during the quarter? And then any updated thoughts on the time line to get the final programs moved offshore and whether that could take place this year or if that's more of a 2027 item?

Mitchell Rock

Brett, thanks for the question. What we would say broadly is we're really aligning our resources with our customers' priorities and our customers' priorities over time can shift. I mean this is a growing business with some moving parts that has a complex transfer. The overall business is contributing, so we're making it better. And then we are looking forward to '27 to complete additional transfer activity. So that's how I would think about it.

Brett Fishbin

All right. Perfect. Perfect. And then I know you guys have the longer-term guidance framework, which is 12% to 18% growth, generally 50% organic, which gets to 6% to 9%. You've been above that range in both 2Q and 3Q with double-digit growth. Maybe just any directional comments on what you kind of anticipate for 4Q and into 2027, if 6% to 9% is still kind of the right general baseline range to be thinking about?

Mitchell Rock

Yes. I mean, as you know, we don't give quarterly or annual guidance. I think we're comfortable with the 6% to 9%. Obviously, we've had 2 good quarters. Q4 is traditionally softer -- and as we've moved more activity to the DR, I expect that to continue to be true because we have more holiday shutdowns down there. So I think we're comfortable with the organic growth range and then the overall 12% to 18% with regard to organic and inorganic growth combined.

Brett Fishbin

Perfect. And last question for me. You guys noted in the press release and then again on the call that some of the additional capacity you're adding to DAS Medical could support double-digit growth for that business next year. So just interested in any more color around your early assumptions here and kind of what gives you confidence and visibility into that range?

Mitchell Rock

Yes, great question. So this has been a 5-year journey of investing in this business. In Q1, we signed an extension to support growth. So we have 3 things going on. We have -- we have the growth that we've invested in as far as supporting that long-term agreement. Two, we'll get the full year benefit of the things that we've launched this year, the programs we've launched this year.

So that -- and then lastly, more broadly, which is exciting is that there are robotic surgical platforms that are gaining market adoption that have been, what I would say, subscale so far, and we'll see some meaningful contribution as we move into '27 and beyond. So it's a great story.

Operator

Our next question comes from the line of Andrew Cooper with Raymond James.

Andrew Cooper

Maybe first, just on margins and maybe how it plays into the AJR transition. I mean you've continued to drive margins higher despite the, let's just say, lack of capture of the upside that you expect when those transitions do happen or the final transfers happen. So what's kind of enabled you to continue pushing higher from that perspective on the gross margin side? And how should we expect that to trend in '27 when those transfers do finalize?

Mitchell Rock

Andrew, great question. What I would think broadly about the portfolio is I would think we're focused on revenue growth and operating margin. There are puts and takes on the gross margin. So I think we're excited that we've made progress there. And I think it's -- the story is broad across the portfolio, a combination of volume and the team continue to take costs out. So I think we're comfortable in the -- in our range of 28% to 31%, and I think we're settling in at that 29%. So I think we're comfortable thinking about that way.

Andrew Cooper

Okay. Helpful. And then maybe one on kind of some of the M&A commentary and obviously talking about upsizing some of the capacity there. I think it's interesting you called out TPI as well. Is injection molding an area where you think you can add meaningfully from maybe an organic investment perspective? Is that one of the focus areas when we think about M&A? And just how do we think about the comment in the press release around broadening injection molding capabilities?

Mitchell Rock

Yes. I think if you look at our platform from a capability perspective, we have scale in films, foams, fabrics, and we're subscale in some other interesting areas like plastics or extrusion or adhesives. And it's probably the largest space in kind of single-use CDMOs. So it's -- we have seen a lot of assets in that space, and we continue to be thoughtful about how to add it to the portfolio, both from an organic perspective and from an acquisition perspective.

Andrew Cooper

Okay. Helpful. And then maybe just one big picture one. It feels like there's a lot going on in MedTech world in your customer base overall. Has there been any change in tone or aggressiveness around kind of how they're thinking about development work and new product rollouts and ordering patterns, et cetera, as you think about the last, call it, couple of months of conversations you've had with some of these key accounts?

Mitchell Rock

Nothing really sticks out to me. I mean I think ultimately, this -- the macro trends in the space of trying to develop widgets that deliver a better patient outcome and ultimately drive costs out are consistent. So I think we will continue to map our resources to those customer needs.

Operator

Our next question comes from the line of Luke Fingerson with Lake Street.

Luke Fingerson

Mitch, Ron.

First question for you guys. SG&A is up about 20% year-over-year. Should we expect this to keep stepping up into 2027? Or how should we think about that going forward?

Mitchell Rock

Good question. A few points there. There is onetime duplicate CEO costs that will roll off. We do have additional cybersecurity costs that will be permanent. And then we've really invested ahead of growth in terms of the team. And so we suspect that, that will moderate as we grow into those investments by both growing the business organically and adding some businesses to the platform via acquisition.

Luke Fingerson

Got it. And then on capital allocation, you expanded the credit facility and mentioned onboarding larger businesses. How much leverage are you guys willing to run on a larger deal? And then how are you guys thinking about structure when it comes to deal size?

Mitchell Rock

I think we're going to maintain the playbook. We're going to look at continuing to -- our current credit facility is we can borrow at 3.25x EBITDA. And we're just thinking about it in the same way just at a larger scale given the size of the enterprise now.

Operator

That was the last question for today. I now turn the conference back to Mitchell Rock for any closing remarks. Thank you, and over to you, Mitch.

Mitchell Rock

Thank you. Well, thanks, everyone. I just want to thank our customers and our team members. Without those 2 constituents, we wouldn't have a great business. We're super excited about going into 2027, and we appreciate all the support from the investment community. So have a great Thanksgiving and holiday season. We'll talk to you next quarter.

Operator

Thank you, Mitch. The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.